University of Kentucky offers stroke stem cell trial

January 13, 2012, University of Kentucky

The University of Kentucky will be the first site in the state and one of a select few in the entire country participating in the first stages of a groundbreaking study to investigate the effects of MultiStem, a human adult stem cell product, on patients with acute ischemic stroke. The phase II clinical trial, known as Atherys stroke protocol B01-02, was recently approved by UK's institutional review board.

" may have great potential in stroke treatment, and we need to approach it scientifically. We are excited to be the first to bring a clinical trial of stem cells for stroke to Kentucky," said Dr. Michael Dobbs, director of the UK HealthCare Stroke Affiliate Network and principal investigator on the stem cell trial.

Despite recent advances in interventional ischemic stroke treatment, medical therapy for the treatment of stroke has largely been limited to tPA, the clot-busting drug that received FDA approval in 1996.

Using stem cells in the treatment of stroke represents a novel approach to treating the damage caused by stroke. Studies of animal models suggest that stem cell therapy may offer a unique neuro-protective effect, and further investigation as to the mechanism of this benefit is currently underway.

MultiStem is also being studied as a potential treatment for a variety of diseases, with the therapy already successfully completing a Phase I trial in patients suffering from Graft Versus Host Disease (GVHD), a potentially deadly complication of in cancer patients.

"UK's selection as one of the first sites for this study exemplifies our position as a national leader in cutting edge and research. By pioneering new approaches to , we are doing our part to ensure that our stroke patients receive the absolute best care possible," Dobbs said.

Explore further: Bone marrow stem cell therapy safe for acute stroke: report

Related Stories

Bone marrow stem cell therapy safe for acute stroke: report

August 31, 2011
Using a patient's own bone marrow stem cells to treat acute stroke is feasible and safe, according to the results of a ground-breaking Phase I trial at The University of Texas Health Science Center at Houston (UTHealth).

Study uses new stem cell therapy in patients up to 19 days after stroke

July 14, 2011
The first Texas patient has been enrolled by researchers at The University of Texas Health Science Center at Houston (UTHealth) in the country's first double-blind clinical trial studying the safety and efficacy of an innovative ...

Use of clot busters for stroke increased from 2005 to 2009, but still low

June 2, 2011
The use of clot-busting drugs to treat acute ischemic stroke increased from 2005 through 2009 — but is still low, according to research reported in Stroke: Journal of the American Heart Association.

Recommended for you

New era for blood transfusions through genome sequencing

May 18, 2018
Most people are familiar with A, B, AB and O blood types, but there are hundreds of additional blood group "antigens" on red blood cells—substances that can trigger the body's immune response—that differ from person to ...

Robots grow mini-organs from human stem cells

May 17, 2018
An automated system that uses robots has been designed to rapidly produce human mini-organs derived from stem cells. Researchers at the University of Washington School of Medicine in Seattle developed the new system.

Scientists uncover a new face of a famous protein, SWI2/SNF2 ATPase

May 17, 2018
A team of Texas A&M and Texas A&M AgriLife Research scientists now have a deeper understanding of a large switch/sucrose non-fermentable (SWI/SNF) protein complex that plays a pivotal role in plant and human gene expression ...

Antibacterial in your toothpaste may combat severe lung disease

May 17, 2018
A common antibacterial substance found in toothpaste may combat life-threatening diseases such as cystic fibrosis, or CF, when combined with an already FDA-approved drug.

Blocking two enzymes could make cancer cells mortal

May 17, 2018
EPFL scientists have identified two enzymes that protect chromosomes from oxidative damage and shortening. Blocking them might be a new anticancer strategy for stopping telomerase, the enzyme that immortalizes tumors.

Emergency contact information helps researchers branch out family tree

May 17, 2018
When you go to the doctor or hospital, one piece of information that you're always asked to provide—in addition to your name, address, and insurance information—is an emergency contact. Often, that person is a blood relative. ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.